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Psoriasis vulgaris (PsV) risk is strongly associated with variation within the major histocompatibility complex (MHC) region, but its
genetic architecture has yet to be fully elucidated. Here, we conducted a large-scale fine-mapping study of PsV risk in the MHC region
in 9,247 PsV-affected individuals and 13,589 controls of European descent by imputing class I and II human leukocyte antigen (HLA)
genes from SNP genotype data. In addition, we imputed sequence variants for MICA, an MHC HLA-like gene that has been associated
with PsV, to evaluate association at that locus as well.We observed thatHLA-C*06:02 demonstrated the lowest p value for overall PsV risk
(p ¼ 1.73 10364). Stepwise analysis revealed multiple HLA-C*06:02-independent risk variants in both class I and class II HLA genes for
PsV susceptibility (HLA-C*12:03, HLA-B amino acid positions 67 and 9, HLA-A amino acid position 95, and HLA-DQa1 amino acid
position 53; p < 5.0 3 108), but no apparent risk conferred by MICA. We further evaluated risk of two major clinical subtypes of
PsV, psoriatic arthritis (PsA; n ¼ 3,038) and cutaneous psoriasis (PsC; n ¼ 3,098). We found that risk heterogeneity between PsA and
PsC might be driven by HLA-B amino acid position 45 (pomnibus ¼ 2.2 3 1011), indicating that different genetic factors underlie
the overall risk of PsV and the risk of specific PsV subphenotypes. Our study illustrates the value of high-resolution HLA and MICA
imputation for fine mapping causal variants in the MHC.Introduction
Psoriasis vulgaris (PsV [MIM 177900]) is a common im-
mune-mediated skin disease characterized by epidermal
hyperplasia, inflammatory cell infiltration, and vascular re-
modeling.1,2 Approximately one-third of PsV-affected indi-
viduals develop a related inflammatory musculoskeletal
condition called psoriatic arthritis (PsA), which is consid-
ered more severe than the other more common PsV
subtype, cutaneous psoriasis (PsC).3 Previous linkage and
association studies havemapped PsV risk to a critical region
spanning ~300 kb within the major histocompatibility
complex (MHC) class I regionon6p21 (this region is termed
PSORS1).4 Subsequent analyses have identified HLA-Cw6
(MIM 142840) as the risk allele of PSORS1.5,6 Although
recent large-scale genome-wide association studies
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frequent four-digit allele equivalent to HLA-Cw6) has
consistently demonstrated the strongest association with
PsV risk.7–12
However, the effects of the genetic architecture of the
MHC region on PsV risk have yet to be fully elucidated. Pre-
vious studies have suggested the existence of other risk var-
iants in addition toHLA-C*06:02 in class I human leukocyte
antigen (HLA) genes (HLA-A [MIM 142800] orHLA-B [MIM
142830]) and class II HLA genes (HLA-DRB1 [MIM 142857],
HLA-DQA1 [MIM146880],HLA-DQB1 [MIM604305],HLA-
DPA1 [MIM 142880], orHLA-DPB1 [MIM 142858]).13–18 In-
vestigators have also studied polymorphisms ofMHCclass I
polypeptide-related sequence A (MICA [MIM 600169]), an
HLA-like gene that does not present antigen.17,19,20 How-
ever, strong and complex linkage-disequilibrium (LD) pat-
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identification of independent risk signals. Moreover, ana-
lyses focusing on the twomajor subsets of PsV have identi-
fied different effect sizes of associated risk alleles (including
HLA-C*06:02) between PsA and PsC, suggesting heteroge-
neous effects of HLA alleles on the two major subpheno-
types.13–16,23
Recently, we devised an analytical approach to fine map
risk of the variants in the MHC region by imputing geno-
types of amino acid polymorphisms in the classical HLA
genes and classical two- and four-digit alleles.24–26 Each
classical four-digit HLA allele corresponds to a unique
amino acid sequence encoded by the HLA gene, and thus
polymorphic residues at each amino acid position could
also be targets of disease-risk association studies. This
approach has been used for successfully fine mapping
HLA alleles of several autoimmune or immune-mediated
diseases, including durable host control of HIV infection
(MIM 609423), seropositive and seronegative rheuma-
toid arthritis (MIM 180300), myasthenia gravis (MIM
254200), and follicular lymphoma (MIM 613024).25–29 In
certain instances, our approach has been able to pinpoint
individual amino acid sites that might account for disease
risk within HLA molecules.25–27
In this study, we aimed to fully characterize the genetic
architecture of the MHC region for PsV. Our goals were (1)
to define the set of risk alleles for PsV at the four-digit HLA
allele and amino acid resolutions, (2) to examine how the
role of MICA in PsV compares to that of other HLA genes,
and (3) to identify a genetic marker that distinguishes the
risk of two subtypes, PsA and PsC. To this end, we applied
our HLA-variant imputation approach to large-scale PsV
GWASs and Immunochip studies comprising 9,247
affected individuals and 13,589 control individuals of
European ancestry. We also expanded our approach to
impute MICA alleles and MICA amino acid polymor-
phisms by constructing a MICA imputation reference
panel. With the imputed MHC sequence variations,
including classical HLA genes and MICA, we fine mapped
the MHC associations with overall PsV risk and specifically
focused on risk comparisons between the PsA and PsC
subphenotypes.Material and Methods
Samples
We used data from 9,247 PsV-affected individuals and 13,589 con-
trol individuals obtained from six case-control PsV data sets,
including four GWASs (the Collaborative Association Study of Pso-
riasis [CASP] and the Genizon, Kiel, and PsA GWASs), a targeted
deep follow-up study of CASP (the CASP-DFU), and one Immuno-
chip-based data set of 3,723 affected and 7,595 control subjects
(the Psoriasis Association Genetics Extension [PAGE] study), for
a total of 9,247 affected and 13,589 control individuals (Table
S1, available online).7,9,12 Genotype data of the studies were gener-
ated and stringently quality-control (QC) filtered as described
elsewhere,7,9,12 and all samples were confirmed to be unrelated in-
dividuals of European ancestry according to self-reported ethnicityThe Amerand results of principal-component (PC) analysis. All participating
individuals provided written informed consent and were recruited
according to the protocols approved by the institutional review
board of each institution.Phenotype Classification
All PsV-affected individuals were diagnosed by a dermatologist.
Diagnosis of PsA was confirmed by a rheumatologist according
to the Classification Criteria for Psoriatic Arthritis.30 Individuals
who had had PsV for 10 or more years but no signs of PsA were
classified as having PsC. Our data set included 3,038 PsA subjects,
3,098 PsC subjects, and 3,111 subjects of unknown PsA or PsC
status (Table S1).Statistical Analysis
HLA Imputation
For each data set, we used SNP2HLA24 to extract SNP genotypes
located in the MHC region to impute classical two- and four-digit
HLA alleles of and amino acid polymorphisms encoded by the
eight class I and class II HLA genes (HLA-A, HLA-B, HLA-C, HLA-
DRB1, HLA-DQA1, HLA-DQB1, HLA-DPA1, and HLA-DPB1). We
conducted HLA imputation for each data set separately by using
HLA and SNP genotypes from the Type 1 Diabetes Genetics Con-
sortium (T1DGC; n ¼ 5,225), which has demonstrated a high
imputation accuracy for classical HLA alleles,24,26,31 as a reference
panel. We obtained information on HLA-gene polymorphisms
from the IMGT/HLA Database.32 Amino acid sequences encoded
by the imputed HLA genes are indicated in Figure S1. For HLA
amino acid positions, we indicate the start codon of the mature
HLA protein as position 1, and we label the codon 50 to this site
as 1.24 SNP2HLA checks concordance of allele strands of the
A/T or G/C SNPs between the data set and the reference panel
on the basis of allele-frequency comparison.24 We applied postim-
putation QC criteria of MAF > 0.1% for the association analysis.
MICA Imputation
To expand our HLA imputation protocol into HLA-like genes, we
constructed a reference panel for imputation of MICA variants.
We obtained classical four-digit MICA alleles for the subjects
from a subset of the PsA data set (n ¼ 1,046). These samples
were not selected in any particular way. We obtained MICA amino
acid sequences from the IMGT/HLA Database32 and the encoded
MICA amino acid polymorphisms of the subjects, as well as the
genotypes of MICA classical alleles and the genotyped SNPs in
the MHC region. Using the constructed MICA reference panel
and SNP2HLA,24 we imputed MICA variants for the other data-
set collections. Imputed genotypes of the MICA alleles and
MICA amino acid polymorphisms were extracted and merged
into those obtained from HLA imputation mentioned in the pre-
vious section. We empirically assessed the accuracy of imputing
MICA variants by additionally genotyping MICA in a subset of
the subjects from the PAGE Immunochip data set (n ¼ 104) and
comparing concordances of the imputed and genotyped classical
MICA variants as described elsewhere.24,26Statistical Framework for Association Analysis
We used the following analyses to test associations between HLA
variants and risk of four binary phenotypes: (1) overall analysis
of PsV susceptibility (PsV-affected versus control individuals),
(2) stratified analysis of PsA susceptibility (PsA-affected versus
control individuals), (3) stratified analysis of PsC susceptibil-
ity (PsC-affected versus control individuals), and (4) intra-PsVican Journal of Human Genetics 95, 162–172, August 7, 2014 163
analysis directly comparing PsA to PsC (PsA-affected versus PsC-
affected individuals). For each phenotype, we assessed variant
risk with a logistic-regression model assuming additive effects of
the allele dosages in the log-odds scale and their fixed effects
among the data-set collections. We defined HLA variants to
include biallelic SNPs in the MHC region, two- and four-digit
biallelic classical HLA or MICA alleles, biallelic HLA or MICA
amino acid polymorphisms for respective residues, and multial-
lelic HLA or MICA amino acid polymorphisms for respective
positions. To account for potential population-based and data-
set-specific confounding factors, we included the top ten PCs
and an indicator variable for each data set as covariates. For
HLA variants with m alleles (m ¼ 2 for biallelic variants and
m > 2 for multiallelic variants), we included m  1 alleles,
excluding the most frequent allele as a reference, as independent
variables in the regression model. This resulted in the following
logistic-regression model:
logðoddsÞ ¼ b0 þ
Xm1
j¼1
b1;jxj þ
XK
k¼1
 XL
l¼1
b2;k;lyk;l þ b3;kzk
!
þ ε;
where b0 is the logistic-regression intercept and b1,j is the additive
effect of the dosage of allele j for the variant xj. K and L are
numbers of the collections and PCs enrolled in the analysis. yk,l
is the lth PC for the kth collection, and zk is the indicator variable
for the collection-specific intercept. b2,k,l and b3,k parameters
are the effects of yk,l and zk, respectively. An omnibus p value
of the variant (pomnibus) was obtained by a log-likelihood ratio
test comparing the likelihood of the null model against the like-
lihood of the fitted model. We assessed the significance of the
improvement in fit by calculating the deviance (23 the log like-
lihood ratio), which follows a c2 distribution withm  1 degree(s)
of freedom.
Conditional Association Analysis
For conditional association analysis, we considered the regression
model including the additional HLA variants as covariates. When
conditioning on specific HLA amino acid position(s), we included
multiallelic variants of the amino acid residues as covariates.
When conditioning on specific HLA gene(s), we included all
two- and four-digit classical alleles of the HLA gene(s) (but not
alleles with strong correlations [R2 > 0.97]). We consecutively
selected the HLA variants to be included as covariates for each
HLA gene separately in a forward-type stepwise fashion until no
variant satisfied the genome-wide significant threshold (p <
5.0 3 108). We tested a multivariate full regression model by
including the HLA-C, HLA-B, HLA-A, and HLA-DQA1 risk variants
identified by the stepwise regression analysis as covariates and
excluding the most frequent allele (or residue) from each locus
(or amino acid position) as a reference allele (Table 1). Assuming
a PsV prevalence of 2.0%, we estimated phenotypic variance ex-
plained by the risk HLA alleles and amino acid polymorphisms
on the basis of the effect sizes obtained from the multivariate
regression analysis and a liability threshold model.2
Testing for Discordant Effect Sizes on PsA and PsC
We tested whether the effect sizes of m classical four-digit alleles
of the HLA gene had concordant risks between PsA and PsC, as
described elsewhere.26 For each of the two compared phenotypes
(PsA-affected versus control individuals and PsC-affected versus
control individuals), we calculated multivariate odds ratios
(ORs) of m  1 alleles by including them as binary independent164 The American Journal of Human Genetics 95, 162–172, August 7variables in the regression model, where the most frequent allele
was excluded as a reference. Let bPsA,1, ., bPsA,m1 and vPsA,1, .,
vPsA,m1 be the multivariate log ORs and their variances,
respectively, in PsA-affected versus control individuals, and let
bPsC,1,., bPsC,m1 and vPsC,1,., vPsC,m1 be those in PsC-affected
versus control individuals. We evaluated discordance of the effect
sizes between the compared phenotypes (pheterogeneity) by testing
the statistic
Xm1
i¼1

bPsA;i  bPsC;i
2
vPsA;i þ vPsC;i ;
which follows a c2 distribution with m  1 degrees of freedom
under the null hypothesis of concordant effects.Results
HLA and MICA Imputation
After imputation of HLA and MICA, we obtained geno-
types for 7,078 SNPs in the MHC region (29.6–33.2 Mb
at chromosome 6, UCSC Genome Browser hg18), 105
two-digit HLA or MICA alleles, 176 four-digit HLA or
MICA alleles, and 438 amino acid polymorphisms encoded
by HLA orMICA genes. Imputation ofMICA demonstrated
high concordance between genotyped and imputed geno-
types (88.9% for both two- and four-digit alleles), which
was comparable to that reported for imputation of other
HLA genes.24–26
HLA-C*06:02 Has the Strongest Association with PsV
Risk
Unsurprisingly, when we tested the imputed variants in
the MHC region for overall PsV risk (PsV-affected versus
control individuals), the top association signal mapped
to HLA-C (Figures 1A and 2A; Table S2). The most strongly
associated variant was the classical HLA-C*06:02 allele
(p ¼ 1.73 10364), highly consistent with previous reports
that HLA-C*06:02 has the strongest association with PsV
risk.7–12,17,18 We observed that no HLA-C amino acid poly-
morphism was more strongly associated than HLA-C*
06:02 (the smallest p value, pomnibus ¼ 4.5 3 10250, was
at HLA-C amino acid position 156; Figure 3A). When con-
ditioning on HLA-C*06:02, we observed the top associa-
tion signal at the four-digit classical allele of HLA-C*
12:03 (p ¼ 2.5 3 1025). After conditioning on HLA-C*
06:02 and HLA-C*12:03, we found that no association
exceeded the genome-wide significance threshold for the
HLA-C variants (p > 5.0 3 108). These results suggest
that multiple classical HLA-C alleles, exemplified by HLA-
C*06:02, explain the influence of HLA-C on PsV risk.
PsV Risk Is Associated with Multiple Class I and Class
II HLA Genes
We then investigated additional HLA-variant PsV risk
independent of HLA-C. When we conditioned on all
classical HLA-C alleles, we observed a significant inde-
pendent association at HLA-B amino acid position 67
(pomnibus ¼ 1.8 3 1045; Figures 2B and 3B). Stepwise, 2014
Figure 1. Plots of Nominal Association
between the MHC Variants and PsV and
Its Subphenotypes of PsA and PsC
Each diamond represents the –log10(p) of
the variants, including SNPs, classical
HLA orMICA alleles, and amino acid poly-
morphisms encoded by the HLA genes or
MICA. The dotted horizontal line repre-
sents the significance threshold of p ¼
5.0 3 108. The bottom panel shows the
physical positions of the HLA genes,
MICA, and PSORS1 on chromosome 6
(UCSC Genome Browser hg18). We tested
four binary phenotypes: (A) PsV-affected
versus control individuals, (B) PsA-
affected versus control individuals, (C)
PsC-affected versus control individuals,
and (D) PsA-affected versus PsC-affected
individuals.regression analysis of HLA-B variants further identified an
independent association at position 9 (pomnibus ¼ 1.5 3
108). When we conditioned on HLA-C and HLA-B, we
observed a significant independent association at HLA-A
amino acid position 95 (pomnibus ¼ 2.1 3 1036; Figures
2C and 3C). Stepwise analysis did not identify additional
association within HLA-A. When we conditioned on the
effects of HLA-C, HLA-B, and HLA-A, we observed a signif-
icant independent association at HLA-DQa1 amino acid
position 53 (pomnibus ¼ 4.2 3 1010; Figures 2D and 3D).
Stepwise analysis did not identify an additional association
within HLA-DQA1. When conditioning on HLA-C, HLA-B,
HLA-A, and HLA-DQA1, we observed no other significant
associations (p > 5.0 3 108; Figure 2E). These results
demonstrate that PsV risk within the MHC region can be
explained by combinations of multiple class I and class II
HLA genes.
To highlight specific HLA alleles or amino acid residues
that confer overall PsV risk, we defined a multivariate full
regression model including all the identified risk variants
of HLA-C, HLA-B, HLA-A, and HLA-DQA1 (Table 1; Table
S3). For HLA-C, we observed increased risk associated
with HLA-C*06:02 (OR ¼ 3.26, 95% confidence interval
[CI] ¼ 3.02–3.52, p ¼ 2.1 3 10201) and HLA-C*12:03
(OR ¼ 1.38, 95% CI ¼ 1.26–1.52, p ¼ 6.5 3 1012). ForThe American Journal of Human GHLA-B, we observed increased risk
associated with Cys67 (OR ¼ 1.56,
95% CI ¼ 1.45–1.67, p ¼ 6.0 3
1035), Met67 (OR ¼ 1.44, 95% CI ¼
1.30–1.58, p ¼ 2.6 3 1013), and
Asp9 (OR ¼ 1.33, 95% CI ¼ 1.21–
1.45, p ¼ 1.6 3 109). HLA-A Val95
(OR ¼ 1.31, 95% CI ¼ 1.25–1.38,
p ¼ 4.7 3 1028) and HLA-DQa1
Arg53 (OR ¼ 1.07, 95% CI ¼ 1.01–
1.13, p ¼ 0.016) also demonstrated
increased risk. In combination,
these risk variants explained 6.7% of
phenotype variance of PsV under theassumption of 2.0% of disease prevalence,2 whereas HLA-
C*06:02 alone explained only 4.9% of the variance.
Risk Heterogeneity between PsA and PsC Is Explained
by HLA-B
Next, we conducted an analysis focusing on subpheno-
types of PsA and PsC. Overall, the association results of
the PsA case-control analysis and of the PsC case-control
analysis were similar to those of the PsV case-control anal-
ysis (Figures 1A–1C). The classical HLA-C*06:02 allele
demonstrated the lowest p value among the HLA variants
in the MHC region. Stepwise association analyses, sepa-
rately conducted for the PsA case-control analysis and
the PsC case-control analysis, both revealed independent
contributions of other class I HLA genes (HLA-B and
HLA-C; Figure S2; Table S2). We did not observe indepen-
dent signals for HLA class II genes in this stratified analysis,
perhaps as a result of reduced statistical power.
Surprisingly, when we directly assessed comparative risk
between PsA and PsC subjects, we found the lowest p value
of the nominal association signal at HLA-B amino acid
position 45 (pomnibus ¼ 2.2 3 1011; Figures 1D and 2F)
rather than at HLA-C alleles. After conditioning on HLA-B
amino acid position 45, or all classical HLA-B alleles, we
observed no significant association in the MHC regionenetics 95, 162–172, August 7, 2014 165
Figure 2. Plots of Stepwise Conditional
Association of the Variants in the MHC
Region
(A–E) Stepwise analysis of HLA-C, HLA-B,
HLA-A, and HLA-DQA1 in PsV-affected
versus control individuals.
(F andG) Stepwise analysis ofHLA-B in PsA
versus PsC individuals. Each diamond rep-
resents the –log10(p) of the variants,
including SNPs, classical HLA or MICA
alleles, and amino acid polymorphisms
encoded by the HLA genes or MICA. The
dotted horizontal line represents the sig-
nificance threshold of p ¼ 5.0 3 108.
The most strongly associated amino acid
polymorphisms and HLA classical alleles
are labeled when their associations satis-
fied p < 5.0 3 108.(p> 5.03108; Figures 2Gand3E).Of theHLA-Baminoacid
residues at position 45, HLA-B Glu45 increased PsA suscepti-
bility in comparison to PsC susceptibility (OR ¼ 1.46, 95%
CI ¼ 1.31–1.62, p ¼ 2.9 3 1012; Table 2; Table S2). Exam-
ining the classical alleles, we noted that HLA-B*27, a risk
allele for another arthritic disease, ankylosing spondylitis
(MIM 106300),33 demonstrated the lowest p value for PsA166 The American Journal of Human Genetics 95, 162–172, August 7, 2014versus PsC association (p¼ 1.23 104;
Figure 4; Table S4) butmuch less signif-
icantly than HLA-B Glu45. We note
that HLA-B*27, along with HLA-B*38,
HLA-B*39, and a number of other
alleles, carries Glu at position 45.
Previous studies comparing PsA
and PsC have suggested that HLA-C*
06:02 shows increased PsC risk but
decreased PsA risk,13,14 and our study
replicated this finding in a concor-
dant directional effect (p ¼ 9.4 3
106 for PsA versus PsC individuals).
However, the differential impact of
HLA-C*06:02 on PsA and PsC risk
disappeared after we conditioned on
HLA-B amino acid position 45 (p ¼
0.12), suggesting that this reduced ef-
fect was the result of linkage to HLA-
B. In contrast, the effect of HLA-B
amino acid position 45 with respect
to PsA versus PsC risk retained signif-
icance even after we conditioned on
HLA-C*06:02 (pomnibus ¼ 2.2 3 107).
We evaluated effect-size (OR) het-
erogeneity in classical four-digit al-
leles of the HLA genes between the
two association analyses of PsA-
affected versus control individuals
and PsC-affected versus control indi-
viduals. Among the eight class I and
class II HLA genes that we evaluatedin the overall PsV case-control analysis, the HLA-B and
HLA-C alleles showed significant risk heterogeneity
(pheterogeneity ¼ 5.8 3 1014 and pheterogeneity ¼ 2.9 3 106,
respectively, with a significance threshold of p < 0.05/8 ¼
0.0073). When we conditioned on HLA-B amino
acid position 45, risk heterogeneity diminished in both
HLA-B and HLA-C classical alleles (pheterogeneity > 0.01).
Figure 3. Plots of Stepwise Conditional Association of the HLA Amino Acid Polymorphisms and Classical HLA Alleles
(A–D) Stepwise analysis of HLA-C, HLA-B, HLA-A, and HLA-DQA1 in PsV-affected versus control individuals.
(E) Stepwise analysis ofHLA-B in PsA-affected versus PsC-affected individuals. Each diamond represents the –log10(pomnibus) of the amino
acid polymorphism encoded by the HLA gene. The colored horizontal line represents the –log10(pomnibus) of themost strongly associated
classical allele of the HLA gene. The dotted horizontal line represents the significance threshold of p ¼ 5.0 3 108. The most strongly
associated amino acid polymorphisms and HLA classical alleles are labeled when their associations satisfied p < 5.0 3 108.In contrast, when we conditioned on HLA-C*06:02, risk
heterogeneity diminished for the classical HLA-C alleles
(pheterogeneity¼ 0.018), but not in the classicalHLA-B alleles
(pheterogeneity ¼ 6.53 105). These results demonstrate that
the risk heterogeneity between PsA and PsC primarily de-
rives from HLA-B, but not HLA-C (or other), genes.The AmerNo Apparent Contribution of MICA to Psoriasis Risk
MICA variants demonstrated nominally significant associa-
tions with PsV, PsA, and PsC risk (the lowest p value,
pomnibus ¼ 2.2 3 10180, was at MICA amino acid position
298 for PsV-affected versus control individuals; Table S2).
However, after we conditioned on HLA-C and HLA-B, noican Journal of Human Genetics 95, 162–172, August 7, 2014 167
Table 1. Association Results of the HLA Variants for Overall PsV Risk in Multivariate Regression Model
HLA Variant
Frequency PsV-Affected versus Control Individuals
PsV Control OR (95% CI)a pa
Classical HLA-C Alleles
HLA-C*06:02 0.23 0.093 3.26 (3.02–3.52) 2.1 3 10201
HLA-C*12:03 0.073 0.056 1.38 (1.26–1.52) 6.5 3 1012
Other four-digit HLA-C alleles 0.70 0.85 reference reference
HLA-B Amino Acid Position 67
Cys 0.16 0.12 1.56 (1.45–1.67) 6.0 3 1035
Met 0.12 0.046 1.44 (1.30–1.58) 2.6 3 1013
Tyr 0.12 0.16 1.00 (0.93–1.07) 0.93
Phe 0.21 0.26 1.00 (0.93–1.08) 0.99
Ser 0.39 0.42 reference reference
HLA-B Amino Acid Position 9
Asp 0.096 0.11 1.33 (1.21–1.45) 1.6 3 109
Tyr 0.70 0.67 reference reference
His 0.20 0.22 0.87 (0.82–0.92) 1.6 3 106
HLA-A Amino Acid Position 95
Val 0.34 0.29 1.31 (1.25–1.38) 4.7 3 1028
Ile 0.56 0.59 reference reference
Leu 0.099 0.12 0.89 (0.83–0.95) 7.0 3 104
HLA-DQa1 Amino Acid Position 53
Arg 0.37 0.29 1.07 (1.01–1.13) 0.016
Lys 0.39 0.43 reference reference
Gln 0.25 0.29 0.91 (0.86–0.96) 9.3 3 104
Abbreviations are as follows: CI, confidence interval; OR, odds ratio; and PsV, psoriasis vulgaris.
aObtained from the multivariate full regression model including the HLA-C, HLA-B, HLA-A, and HLA-DQA1 risk variants identified by the stepwise regression analysis.MICA variants showed independent association signals (p>
5.0 3 108 for any of the four tested phenotype compari-
sons). Previous studies have suggested independent effects
of severalMICA variants, such asMICA*016,MICA*008:01,
andMICA amino acid position 129, on PsVor its subpheno-
types,19,20 but our study did not observe apparent associa-
tions of these variants when we conditioned on HLA-C*
06:02 or HLA-B amino acid position 67 (p > 0.017). We
note that no significant association was observed in the
MICA variants in direct comparison between PsA subjects
andPsC subjects (p>5.03108). Therefore, our studycould
not identify an independent contributionofMICAon risk of
psoriasis and its clinical subtypes.Discussion
In this study, we fine mapped PsV risk within the MHC
region. In addition to imputing variants of HLA genes,
we evaluated risk of the HLA-like gene MICA by creating
a MICA reference panel that empirically demonstrated168 The American Journal of Human Genetics 95, 162–172, August 7high imputation accuracy. Our study identified multiple
HLA-C*06:02-independent risk variants of both class I
and class II HLA genes for PsV susceptibility (HLA-B,
HLA-A, and HLA-DQA1), but no apparent risk attributable
toMICA. We also observed that risk heterogeneity between
PsA and PsC could be explained by polymorphisms of a
single amino acid site encoded by HLA-B, suggesting that
different genetic architectures underlie the overall risk of
PsV and that of its subphenotypes. To our knowledge,
ours is the largest HLA fine-mapping study of PsV associa-
tions in theMHC to date and defines genetic heterogeneity
between PsA and PsC subphenotypes.
HLA-C*06:02 has the strongest association with PsV risk,
as reported previously.7–12,17,18 We demonstrated that no
single HLA-C amino acid polymorphismwasmore strongly
associated than theHLA-C*06:02 classical allele, suggesting
that the haplotype sequence including HLA-C*06:02 itself
should be the origin of PsV risk. Several hypotheses might
explain this. Clop et al. reported noncoding regulatory
variants that are located in enhancer motifs and that are
unique to the HLA-C*06:02 haplotype.34 A combination, 2014
Table 2. Association Results of HLA Variants for Subphenotype
Risk Comparisons of PsA and PsC
HLA Variant
Frequency
PsA-Affected versus PsC-Affected
Individuals
PsA PsC OR (95% CI) p
HLA-B Amino Acid Position 45 (Nominal)
Glu 0.43 0.33 1.46 (1.31–1.62) 2.9 3 1012
Thr, Lys, Met 0.57 0.67 reference reference
Abbreviations are as follows: CI, confidence interval; OR, odds ratio; PsA,
psoriatic arthritis; and PsC, cutaneous psoriasis.
Figure 4. Associations of Classical HLA-B Alleles and HLA-B
Amino Acid Position 45 for PsA versus PsC Individuals
The –log10(p) of HLA-B classical two- and four-digit HLA-B alleles
and HLA-B amino acid residues at position 45 in PsA versus PsC
individuals. HLA-B Glu45 demonstrated the strongest association
(p ¼ 2.9 3 1012; highlighted with a red circle), whereas the HLA-
B classical alleles showed much smaller effects (p > 1.03 104).of the polymorphisms in multiple HLA-C amino acid sites
could effectively tag HLA-C*06:02.35 We did observe a
more modest independent effect at HLA-C*12:03 in addi-
tion to the large HLA-C*06:02 effect; Helms et al. reported
that HLA-C*06:02 and HLA-C*12:03 share several func-
tional domains and peptide-binding pockets of HLA-C.5
We note that HLA-C*12:03 did not show an independent
association signal after we conditioned on HLA-C*06:02
and every classical HLA-B allele (p ¼ 0.12), suggesting the
possibility that the observed HLA-C*12:03 association
might reflect risk at otherHLA-B alleles in LD. Further func-
tional studies will be necessary for elucidating the role of
HLA-C in PsV risk.
In contrast, outside of HLA-C, amino acid polymor-
phisms (HLA-B amino acid positions 67 and 9, HLA-A
position 95, and HLA-DQa1 position 53) demonstrated
stronger associations than did classical alleles HLA-B,
HLA-A, and HLA-DQA1. All of these amino acid sites
were located within the HLA antigen binding (Figure 5
and Figure S3). Positions 67 and 9 in HLA-B have been
identified in HLA fine-mapping studies for other im-
mune-related diseases.25–27 We note that LD structures be-
tween the amino acid positions could yield potential
ambiguity in fine mapping of the causal amino acid posi-
tion, and this might be clarified with larger studies.
The contribution of HLA-like genes to immune-related
disease risk has long been a topic of discussion.38,39
Although our imputation of MICA alleles was highly accu-
rate, our study did not observe independent MICA risk of
PsVafterwe conditionedon theneighboring riskHLAgenes
HLA-C and HLA-B. Previous studies focusing on MICA risk
did not apply robust conditioning on all classical HLA-C
andHLA-B alleles and thus could have potentially reflected
the associations ofHLA-C andHLA-B via LDwith them.19,20
Here, we were able to successfully decompose the genetic
architecture of PsA and PsC to a shared component and a
subphenotype-specific component.Our studydemonstrates
that theHLA gene associatedwith the risk heterogeneity be-
tween PsA and PsC (HLA-B) is distinct from the HLA gene
most associated with overall PsV risk (HLA-C). Previous
studies have reported that HLA-C*06:02 has different effect
sizes for PsA and PsC, naturally leading to a hypothesis
that the heterogeneity is driven by the difference in HLA-
C, the major risk factor.13–16,23 However, our observation isThe Amermore concordant with a model where the two PsV subtypes
generally share the samerisk alleles, includingHLA-C*06:02,
but differ at a specific locus that contributes to subtype
differences.
HLA-Baminoacidposition45 is thedrivingMHCposition
that modulates differential risk of PsA and PsV. The effect of
Glu at HLA-B position 45 confers substantial risk of psoriatic
arthritis and explains previously reported associations at
HLA-B*27. This site is located within the binding groove of
HLA-B and is classifiedasoneof the functionalpockets influ-
encing receptor cell-surface expression or antigen peptide
binding or presentation.40 Being able to clinically distin-
guish those individuals who have isolated skin disease
(PsC) from thosewhodevelop joint disease (PsA)has clinical
importance. PsA often occurs in addition to psoriatic skin
disease and almost always requires systemic therapy, for
example, with anti-TNF or other biologic medications, for
the prevention of destructive joint disease. In contrast, PsC
can in many instances be managed with topical treatments
alone.3 Our findings might contribute to utilizing informa-
tion on HLA variants to improve diagnostic approaches for
clinical subphenotypes, as suggested for other complex dis-
eases.26 There is a possibility that the HLA-B45 amino acid
residue tags otherHLA-Bdriving risk variants at other amino
acid sites, although we observed only limited LD between
these sites (Figure S4).We also note that ourmethod of eval-
uatingORheterogeneity (i.e., pheterogeneity) might be conser-
vative because of shared control subjects in the PsA and PsC
case-control analyses. Further studies will be required for
elucidating the functional mechanisms that result in differ-
ential PsA and PsC risk.
In summary, our study finemapped risk of multiple class
I and class II HLA genes in PsV and its subphenotypesican Journal of Human Genetics 95, 162–172, August 7, 2014 169
Figure 5. 3D Ribbon Models for HLA-B
HLA-B structures are based on Protein Data Bank entry 2bvp36 and
were prepared with UCSF Chimera version 1.7.37 Amino acid
position 67 and 9 residues associated with overall PsV risk are
highlighted as red and pink spheres, respectively. An amino acid
position 45 residue associated with subphenotype risk hetero-
geneity (PsA versus PsC) is highlighted as a green sphere.through large-scale HLA and MICA imputation. Our study
should contribute to our understanding of HLA variants in
the etiology of PsV.Supplemental Data
Supplemental Data include four figures and four tables and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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